Incepta Pharmaceuticals Ltd. is a leading pharmaceutical company in Bangladesh established in the year 1999. The company has a very big manufacturing facility located at Savar, 35 kilometer away from the center of the capital city Dhaka. Incepta began its operation with a handful of highly skilled and dedicated professionals guided by an able leadership. Proper strategic planning, technical excellence, swift and timely decisions helped us achieve our objectives leading to much faster growth. Incepta was able to anticipate the need of the market and provide the right product at the right time. High focus on R&D investment from the very beginning made possible the introduction of quality products ahead of its competitors in most cases. Incepta Pharmaceuticals Ltd. is now the 2nd largest company of the country and recognized as the fastest growing of the top five manufacturing company in the country. Incepta now has one of the largest and competent sales force and large distribution network of its own, operated from 18 different locations throughout the country. A marketing team composed of pharmacists and doctors are at the core of the marketing operation. These professionals play a crucial role in providing the necessary strategic guideline for the promotion of its product. The company has very innovative plan to become a most renowned pharmaceutical company in the world by improving research based dosage form manufacturing within a very short period.
Incepta Pharmaceuticals was produced its first product, ranitidine, in December of 1999. The company produces various types of dosage forms which include tablets, capsules, oral liquids, ampoules, dry powder vials, powder for suspension, nasal sprays, eye drops, creams, ointments, lotions, gels, prefilled syringes, liquid filled hard gelatin capsules, lyophilized injections, human vaccine etc. Since its inception, Incepta has been launching new and innovative products in order to fulfill unmet demand of the medical community. The company specializes in value added high technology dosage forms like sustained release tablets, quick mouth dissolving tablets, effervescent tablets, barrier coated delayed release tablets, prefilled syringe products, Insulin and Insulin analogue and biological products, among others . It has established a modern research and development laboratory for the development of new, advanced dosage forms for various drugs and devices like poorly soluble drugs, dry powder inhalers, coated pellets, modified release products, taste masked preparation etc. A vast number of different types drugs are produced by Incepta every year, i.e., anesthetics (Nordrine), analgesics, anti anginal, antihistamine, anti pyretic, anti diabetic, antifungal, antiemetic, anti migraine, anti protozoal, diuretic, gynecological, hepatitis B medications, various nutrient supplements, ophthalmic, vitamins and minerals, antihypertensive, antiulcerant, and so on. Besides, many drugs are under research to develop soon. The company sells its products in Bangladesh and plans to begin exporting to both developed and developing countries around the world.
The country has a large generic market, and large companies are beginning to have success overseas. Beginning in 2000, Incepta has been launching new and innovative products at a faster pace than its competitors. Incepta now has one of the largest and competent sales force and large distribution network of its own, operated from 18 different locations throughout the country. However, despite the country possessing huge manufacturing capabilities, the complete lack of R&D in domestic companies could cause the market to stagnate. Incepta has a very competent sales team, which promotes the specialties throughout the country. The company virtually covers every single corner of the rural as well as urban area of Bangladesh. On 15th January 2011, Incepta implemented globally...
Please join StudyMode to read the full document